We are live on ! Find out more
PPCB

Propanc Biopharma

4 hedge funds and large institutions have $71.5K invested in Propanc Biopharma in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more capital invested

Capital invested by funds: $48.7K → $71.5K (+$22.8K)

2.01% more ownership

Funds ownership: 0.09%2.1% (+2%)

33% less funds holding

Funds holding: 64 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
1
Reduced
Closed
5
Calls
Puts
Net Calls
Net Calls Change

PPCB Hedge Fund Activity: Q2 2026 in Review

4 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Propanc Biopharma (PPCB) for Q2 2026, worth a combined $71.5K — up 47% from $48.7K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PPCB and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Jane Street, adding an estimated $42.8K. The largest seller was UBS Group, exiting entirely with an estimated $19.4K sold.

  • 4 institutional investors held Propanc Biopharma (PPCB) as of Q2 2026, down from 6 in Q1 2026.
  • Funds reported $71.5K of Propanc Biopharma stock for Q2 2026, up 47% quarter-over-quarter.
  • 3 funds opened new Propanc Biopharma positions in Q2 2026 and 5 closed out, a net change of -2 holders.
  • The largest Propanc Biopharma buyer in Q2 2026 was Jane Street, an estimated $42.8K added.
  • The largest Propanc Biopharma seller in Q2 2026 was UBS Group, an estimated $19.4K sold.

Based on aggregated 13F filings for Q2 2026.